In the new scenario of anticancer immune therapies, including adaptive transfer of tumor infiltrating lymphocytes (TILs) and immune check point blockade (ICB), mechanisms of resistance have been linked to genetic alteration in IFNAR signaling and antigen processing and presenting machinery genes [96,97]. This evidence concerns the gene IFNAR1 and neoplasm.